Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review

Clin Lung Cancer. 2019 May;20(3):e251-e255. doi: 10.1016/j.cllc.2018.12.004. Epub 2018 Dec 19.

Authors

Yalun Li¹, Rui Zhang¹, Yongzhao Zhou¹, Juan Song¹, Wenxin Luo¹, Panwen Tian², Weimin Li¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China.
² Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China; Lung Cancer Treatment Center, West China Hospital, Sichuan University, Sichuan, China. Electronic address: mrascend@163.com.

PMID: 30638795
DOI: 10.1016/j.cllc.2018.12.004

No abstract available

Keywords: Combination therapy; EGFR-TKIs; Leptomeningeal metastases; MET inhibitors; NSCLC.

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Review

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / secondary
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Circulating Tumor DNA / cerebrospinal fluid*
Crizotinib / therapeutic use*
Drug Resistance, Neoplasm
Female
Gefitinib / therapeutic use*
Gene Amplification
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Meningeal Neoplasms / drug therapy*
Meningeal Neoplasms / secondary
Middle Aged
Mutation / genetics
Neoplasm Staging
Proto-Oncogene Proteins c-met / antagonists & inhibitors
Proto-Oncogene Proteins c-met / genetics
Remission Induction

Substances

Circulating Tumor DNA
Crizotinib
MET protein, human
Proto-Oncogene Proteins c-met
Gefitinib